Enbiosis is established by professionals in science to bring clinically validated, AI-powered health solutions to market.
2020
02
Recognized by Bayer’s Program, confirming Enbiosis’ role as a high-potential innovator in precision health.
2021
03
Enbiosis expands operations and partnerships, reaching a company valuation, driven by increasing clinical adoption.
2022
04
Enbiosis gains international recognition through awards from Sanofi and the UK Government.
2023
05
Backed by strong clinical outcomes and commercial momentum, Enbiosis reaches a $9 million valuation.
2025
06
Enbiosis continues its international expansion, working with top-tier healthcare providers and delivering proven solutions to thousands of patients.
Vision & Mission
We envision a future in the 21st century where human lifespan could nearly double, accompanied by prolonged health-span and sustained youthful vitality
Redefining human longevity
Doubling lifespan. Sustaining vitality. Leading the future.
A new era of life
Driven by science. Delivered by Enbiosis.
Live longer. Live stronger.
Enbiosis is pioneering the future of human health.
“We are building more than a company — we are building a future where health is at the center of human life.”
Ömer Özkan
CEO & Founder
“Artificial intelligence reveals insights from the microbiome that traditional science cannot see — opening a new era for human health.”
